Comparison
Liraglutide vs. MGF (Mechano Growth Factor)
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
204656-20-2
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
Molecular weight
3751 g/mol
2867.2 g/mol
Half-life
13 h
0.1 h
Sequence
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGYQPPSTNKNTKSQRRKGSTFEERKMechanism of action
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
5
4
of which in humans
4
0
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1